glp 1 drug mechanism of action GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Mechanism of action of GLP-1

83% of peptide-aware Americans want the FDA to make peptides more accessible 83% of peptide-aware Americans want the FDA to make peptides more accessible Days before an FDA advisory committee meets to consider whether seven widely used peptides BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon should become eligible for compounding, a new survey suggests thats what Americans want

Singh RB, Wander GS, Rastogi A, et al

A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

GlobalRPH BPC-157 and TB-500: Background, Indications, Efficacy, and Safety (2025)

Synaptic computation